PT Pyridam Farma Tbk (PYFA.JK)
IDR 212.0
(0.95%)
IDR 212.0
(0.95%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 60.69 Billion IDR | -83.1% |
| 2022 | 421.42 Billion IDR | 401.48% |
| 2021 | 83.73 Billion IDR | 76.11% |
| 2020 | 41.27 Billion IDR | 118.11% |
| 2019 | 22.72 Billion IDR | 2.78% |
| 2018 | 21.81 Billion IDR | 4.76% |
| 2017 | 20.68 Billion IDR | 14.73% |
| 2016 | 19.7 Billion IDR | -0.27% |
| 2015 | 12.71 Billion IDR | -7.26% |
| 2014 | 13.69 Billion IDR | -7.16% |
| 2013 | 14.71 Billion IDR | 50.73% |
| 2012 | 16.06 Billion IDR | 30.02% |
| 2011 | 8.07 Billion IDR | 5.3% |
| 2010 | 6.98 Billion IDR | -5.56% |
| 2009 | 7.39 Billion IDR | 35.56% |
| 2008 | 5.45 Billion IDR | 19.71% |
| 2007 | 4.55 Billion IDR | 4.11% |
| 2006 | 4.37 Billion IDR | 56.11% |
| 2005 | 2.8 Billion IDR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -16.63 Billion IDR | 17.29% |
| 2024 Q3 | -30.03 Billion IDR | -40.4% |
| 2024 Q1 | -15.35 Billion IDR | -60.88% |
| 2023 Q4 | -7.47 Billion IDR | -148.67% |
| 2023 Q2 | -1.07 Billion IDR | -109.52% |
| 2023 Q3 | 15.36 Billion IDR | 1524.52% |
| 2023 Q1 | 11.33 Billion IDR | -95.71% |
| 2023 FY | - IDR | -83.1% |
| 2022 Q2 | 30.54 Billion IDR | 54.7% |
| 2022 Q4 | 263.88 Billion IDR | 1431.62% |
| 2022 FY | - IDR | 401.48% |
| 2022 Q1 | 19.74 Billion IDR | 517.46% |
| 2022 Q3 | -19.81 Billion IDR | -164.88% |
| 2021 Q4 | 3.19 Billion IDR | -83.24% |
| 2021 Q2 | 11.94 Billion IDR | -51.23% |
| 2021 Q1 | 24.48 Billion IDR | 151.73% |
| 2021 Q3 | 19.07 Billion IDR | 59.76% |
| 2021 FY | - IDR | 76.11% |
| 2020 Q2 | 2.36 Billion IDR | -64.29% |
| 2020 FY | - IDR | 118.11% |
| 2020 Q4 | 9.72 Billion IDR | -33.51% |
| 2020 Q3 | 14.62 Billion IDR | 519.26% |
| 2020 Q1 | 6.61 Billion IDR | 3.86% |
| 2019 Q1 | 3.3 Billion IDR | -51.63% |
| 2019 FY | - IDR | 2.78% |
| 2019 Q4 | 6.36 Billion IDR | 34.18% |
| 2019 Q3 | 4.74 Billion IDR | 448.51% |
| 2019 Q2 | 865.36 Million IDR | -73.78% |
| 2018 FY | - IDR | 4.76% |
| 2018 Q4 | 6.82 Billion IDR | 50.56% |
| 2018 Q3 | 4.53 Billion IDR | 404.61% |
| 2018 Q2 | 898.19 Million IDR | -65.63% |
| 2018 Q1 | 2.61 Billion IDR | -9.78% |
| 2017 Q2 | 585.66 Million IDR | -73.47% |
| 2017 Q1 | 2.2 Billion IDR | -41.3% |
| 2017 Q3 | 5.65 Billion IDR | 866.09% |
| 2017 FY | - IDR | 14.73% |
| 2017 Q4 | 2.89 Billion IDR | -48.8% |
| 2016 Q3 | 933.31 Million IDR | -73.28% |
| 2016 Q4 | 3.76 Billion IDR | 303.0% |
| 2016 FY | - IDR | -0.27% |
| 2016 Q2 | 3.49 Billion IDR | 43.26% |
| 2016 Q1 | 2.43 Billion IDR | -51.86% |
| 2015 Q4 | 5.06 Billion IDR | 380.23% |
| 2015 FY | - IDR | -7.26% |
| 2015 Q2 | 2.12 Billion IDR | -49.03% |
| 2015 Q1 | 4.16 Billion IDR | -25.25% |
| 2015 Q3 | 1.05 Billion IDR | -50.31% |
| 2014 FY | - IDR | -7.16% |
| 2014 Q1 | 4.3 Billion IDR | -34.47% |
| 2014 Q2 | 1.27 Billion IDR | -70.41% |
| 2014 Q4 | 5.57 Billion IDR | 150.59% |
| 2014 Q3 | 2.22 Billion IDR | 74.35% |
| 2013 Q4 | 6.57 Billion IDR | 241.0% |
| 2013 Q2 | -143.11 Million IDR | -105.06% |
| 2013 Q1 | 2.82 Billion IDR | -13.13% |
| 2013 FY | - IDR | 50.73% |
| 2013 Q3 | 1.92 Billion IDR | 1447.3% |
| 2012 Q1 | 4 Billion IDR | 1121.67% |
| 2012 FY | - IDR | 30.02% |
| 2012 Q3 | 1.31 Billion IDR | 8.18% |
| 2012 Q4 | 3.25 Billion IDR | 147.07% |
| 2012 Q2 | 1.21 Billion IDR | -69.59% |
| 2011 Q2 | 2.02 Billion IDR | -66.81% |
| 2011 Q4 | 327.93 Million IDR | 141.03% |
| 2011 Q1 | 6.09 Billion IDR | 0.0% |
| 2011 Q3 | -799.27 Million IDR | -139.53% |
| 2011 FY | - IDR | 5.3% |
| 2010 FY | - IDR | -5.56% |
| 2009 FY | - IDR | 35.56% |
| 2008 FY | - IDR | 19.71% |
| 2007 FY | - IDR | 4.11% |
| 2006 FY | - IDR | 56.11% |
| 2005 FY | - IDR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| PT Darya-Varia Laboratoria Tbk | 255.91 Billion IDR | 76.282% |
| PT Merck Tbk | 239.49 Billion IDR | 74.656% |
| PT Phapros, Tbk | 120.77 Billion IDR | 49.743% |
| PT Industri Jamu dan Farmasi Sido Muncul Tbk | 1323.93 Billion IDR | 95.415% |
| PT Tempo Scan Pacific Tbk | 1997.6 Billion IDR | 96.961% |